|
Clinical Implementation of a Polygenic Risk Score (PRS) for Breast Cancer
NCT ID : 03688204
|
Breast Surgery and Oncology
|
Gordon and Grumley
|
|
Integrating Family Caregiver Support into Cancer Clinical Trials
NCT ID : 03069287
|
Cancer Support
|
Saria
|
|
A Phase 1/2a Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab Administered in Combination with Ipilimumab or Ipilimumab Alone in Participants with Unresectable or Metastatic Melanoma Who Have Progressed on Anti-PD-1 Therapy
NCT ID : 03978611
Phase : 1/2a
|
Melanoma, Skin and Soft Tissue Tumors
|
O'Day
|
|
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905)
NCT ID : 03924895
Phase : 3
|
Urology and Urologic Oncology
|
Twardowski
|
|
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)
NCT ID : 03924856
Phase : 3
|
Urology and Urologic Oncology
|
Twardowski
|
|
Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy
NCT ID : 03898180
Protocol Number : MK-7902-011
Phase : 3
|
Urology and Urologic Oncology
|
Twardowski
|
|
StimRouter™ for Pain Management in Post-stroke Shoulder Pain (PSSP)
NCT ID : 03093935
Protocol Number : STMR – PAIN 002 PSSP
|
Brain Tumors & Neuroscience
|
Kesari
|
|
Memantine XR and Pregabalin for Chemotherapy-Induced Peripheral Neuropathy
NCT ID : 03709888
Protocol Number : JWCI-17-0101
|
Brain Tumors & Neuroscience
|
Kesari
|
|
An Exploratory Study of Caregiver Burden Among Family Caregivers of Patients With Cancer
NCT ID : 03069105
|
Cancer Support
|
Saria
|
|
CancerLife: Patient-Driven Solution in Cancer Care
NCT ID : 03371147
|
Cancer Support
|
Saria
|
|
Allogeneic Human Mesenchymal Stem Cells for Alzheimer’s Disease
NCT ID : 02833792
Protocol Number : STEM105-M-AD
Phase : 2
|
Brain Tumors & Neuroscience
|
Kesari
|
|
Overactive Bladder Treatment Using StimRouter Neuromodulation System: A Prospective Randomized Trial
NCT ID : 02873312
Protocol Number : CP-STMR-OAB-002
|
Brain Tumors & Neuroscience
|
Kesari
|
|
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
NCT ID : 02847559
Protocol Number : NU 16C02
Phase : 11
|
Brain Tumors & Neuroscience
|
Kesari
|
|
A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer
NCT ID : 03425292
Protocol Number : JWCI-17-0801
|
Brain Tumors & Neuroscience
|
Kesari
|
|
Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients (STELLAR)
NCT ID : 02796261
Protocol Number : OT-15-001 (20162068)
Phase : 3
|
Brain Tumors & Neuroscience
|
Kesari
|
|
TALAPRO-1: A Phase 2, Open-Label, Response Rate Study of Talazoparib in Men with DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer who Previously Received Taxane-Based Chemotherapy and Progressed on at Least 1 Novel Hormonal Agent (Enzalutamide and/or Abiraterone Acetate/Prednisone)
NCT ID : NCT03148795
Protocol Number : MDV3800-06 (C3441006)
Phase : 2
|
Urology and Urologic Oncology
|
Twardowski
|
|
A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Subjects With Advanced Cancer
NCT ID : NCT03860272
Protocol Number : C-800-01
Phase : 1
|
Melanoma, Skin and Soft Tissue Tumors
|
O'Day
|
|
A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination With Ipilimumab or Nivolumab Monotherapy in Participants With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
NCT ID : NCT03668119
Protocol Number : CA209-848
Phase : 2
|
Melanoma, Skin and Soft Tissue Tumors
|
O'Day
|
|
Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies
NCT ID : 03637764
Protocol Number : ACT15377
Phase : 1 and 2
|
Brain Tumors & Neuroscience
|
Kesari
|
|
Open- Label Trial of Sipuleucel-T Administered to Patients on Active Surveillance for Newly Diagnosed Prostate Cancer
NCT ID : 03686683
Protocol Number : P17-1 (ProVent)
Phase : 3
|
Urology and Urologic Oncology
|
Twardowski
|
|
Intratumoral AST-008 Combined With Pembrolizumab in Patients With Advanced Solid Tumors
NCT ID : 03684785
Protocol Number : AST-008-102
Phase : 1b/2
|
Melanoma, Skin and Soft Tissue Tumors
|
O'Day
|
|
Using Virtual Reality (VR) Models for Preoperative Planning
NCT ID : 03334344
Protocol Number : VR Models
|
Urology and Urologic Oncology
|
Linehan
|
|
An Open-label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients with Relapsed/Refractory Solid Tumors or Hematological Malignancies who Have Wild-Type, Heterozygous, and Homozygous UGT1A1*28 Genotypes
NCT ID : 02680795
Protocol Number : SPI-BEL-106
Phase : I
|
Brain Tumors & Neuroscience
|
Kesari
|
|
A Phase I, Open-Label, Multicenter Study Investigating the Tolerability and Efficacy of UV1 Vaccine in First-Line Malignant Melanoma Patients Planned for Treatment with Pembrolizumab
NCT ID : 03538314
Protocol Number : UV1-hTERT-MM-103
Phase : I
|
Melanoma, Skin and Soft Tissue Tumors
|
O'Day
|
|
Phase II Trial of AV-GBM-1 (Autologous Dendritic Cells Loaded with Autologous Tumor Associated Antigens) as Adjunctive Therapy Following Primary Surgery plus Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma
NCT ID : 03400917
Protocol Number : CL-GBM-P01-US
Phase : II
|
Brain Tumors & Neuroscience
|
Kesari
|
|
ProSTAR: A Phase 1b/2 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, Combined with Enzalutamide or Abiraterone/Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer
NCT ID : 03480646
Protocol Number : 1205-201
Phase : Ib/II
|
Urology and Urologic Oncology
|
Twardowski
|
|
The Efficacy and Safety of UGN-102 as a Chemoablation Agent in Patients With LG NMIBC at Intermediate Risk of Recurrence
NCT ID : 03558503
Protocol Number : TC-BC-12
Phase : 2
|
Urology and Urologic Oncology
|
Linehan
|
|
A Pivotal Randomized Study Assessing Vagus Nerve Stimulation (VNS) During Rehabilitation for Improved Upper Limb Motor Function After Stroke (VNS-REHAB)
NCT ID : 03131960
Protocol Number : MT-St-03
Phase : 3
|
Brain Tumors & Neuroscience
|
Kesari
|
|
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
NCT ID : 03553836
Protocol Number : MK-3475-716
Phase : 3
|
Melanoma, Skin and Soft Tissue Tumors
|
O'Day
|
|
A Phase 2, Open-label Study of ABI-009 (nab-Rapamycin) in Bevacizumab-naïve Patients with Recurrent High-grade Glioma and in Patients with Newly Diagnosed Glioblastoma
NCT ID : 03463265
Protocol Number : GBM-007
Phase : 2
|
Brain Tumors & Neuroscience
|
Kesari
|
|
Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine
NCT ID : 03633110
Protocol Number : GEN-009-101
Phase : 1 and 2
|
Melanoma, Skin and Soft Tissue Tumors Minimally Invasive Chest Surgery and Thoracic Surgical Oncology Urology and Urologic Oncology
|
Twardowski
|
|
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
NCT ID : 03425643
Protocol Number : MK-3475-671
Phase : IIB or IIIA
|
Melanoma, Skin and Soft Tissue Tumors Minimally Invasive Chest Surgery and Thoracic Surgical Oncology
|
O'Day
|
|
A Single-Center, Open-Label, Randomized, Phase II Study of NovoTTF-200A Alone and Combined with Temozolomide in Patients with Low-Grade Gliomas
NCT ID : 02507232
Protocol Number : JWCI-16-1101 (20162693)
Phase : II
|
Brain Tumors & Neuroscience
|
Kesari
|
|
A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Camette-Guerin (BCG) Therapy
NCT ID : 02625961
Protocol Number : MK-3475-057 (20160487)
Phase : II
|
Urology and Urologic Oncology
|
Wilson
|
|
A Phase I Dose Escalation and CNS Pharmacokinetic Study of the ErbB Family Inhibitor Afatinib in Patients with Recurrent or Progressive Brain Cancer
NCT ID : 02423525
Protocol Number : 1200-229 (20161975)
Phase : I
|
Brain Tumors & Neuroscience
|
Kesari
|
|
A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination with Bevacizumab versus Bevacizumab Alone in Patients with Recurrent or Progressive Glioblastoma following Initial Therapy
NCT ID : NCT03149003
Protocol Number : BBI-DSP7888-201G
Phase : II
|
Brain Tumors & Neuroscience
|
Kesari
|
|
Recombinant Human Arginase 1 (RhArg1) in Patients with Advanced, Arginine Auxotrophic Solid Tumors: Dose Escalation, Safety And PK/PD
NCT ID : 02285101
Protocol Number : BCT-100-005
Phase : I
|
Melanoma, Skin and Soft Tissue Tumors
|
O'Day
|
